Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $49.33, for a total value of $739,950.00. Following the completion of the sale, the chief executive officer directly owned 627,540 shares of the company's stock, valued at $30,956,548.20. The trade was a 2.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cameron Turtle also recently made the following trade(s):
- On Monday, March 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $42.19, for a total value of $632,850.00.
- On Monday, February 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $32.80, for a total value of $492,000.00.
Spyre Therapeutics Price Performance
Shares of SYRE opened at $48.98 on Tuesday. Spyre Therapeutics, Inc. has a one year low of $10.91 and a one year high of $51.06. The firm has a market capitalization of $3.85 billion, a P/E ratio of -23.55 and a beta of 2.93. The business has a fifty day moving average of $40.34 and a 200 day moving average of $31.40.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Spyre Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Persistent Asset Partners Ltd purchased a new position in Spyre Therapeutics during the fourth quarter valued at $74,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Spyre Therapeutics by 61.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company's stock valued at $124,000 after acquiring an additional 1,435 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company's stock valued at $71,000 after acquiring an additional 4,092 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Spyre Therapeutics by 182.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company's stock valued at $86,000 after acquiring an additional 3,725 shares in the last quarter. Finally, Martingale Asset Management L P purchased a new position in shares of Spyre Therapeutics in the fourth quarter valued at about $227,000. 80.39% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the company. Leerink Partners upgraded Spyre Therapeutics to a "strong-buy" rating in a research report on Thursday, February 19th. Wells Fargo & Company lifted their target price on Spyre Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Friday, February 20th. Citigroup assumed coverage on Spyre Therapeutics in a research report on Wednesday, December 17th. They set a "buy" rating and a $64.00 target price on the stock. BTIG Research reiterated a "buy" rating and set a $70.00 target price on shares of Spyre Therapeutics in a research report on Tuesday, March 31st. Finally, Stifel Nicolaus lifted their target price on Spyre Therapeutics from $70.00 to $92.00 and gave the company a "buy" rating in a research report on Wednesday, March 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $60.67.
Check Out Our Latest Report on Spyre Therapeutics
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
